Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Nam Hoon | - |
dc.contributor.author | Kim, Sin Gon | - |
dc.date.accessioned | 2021-08-31T04:40:29Z | - |
dc.date.available | 2021-08-31T04:40:29Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/56719 | - |
dc.description.abstract | Fibrates, peroxisome proliferator-activated receptor-alpha agonists, are potent lipid-modifying drugs. 'their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an "add on" to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN DIABETES ASSOC | - |
dc.subject | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject | TYPE-2 DIABETES-MELLITUS | - |
dc.subject | NON-HDL CHOLESTEROL | - |
dc.subject | LDL-CHOLESTEROL | - |
dc.subject | ATHEROGENIC DYSLIPIDEMIA | - |
dc.subject | REDUCING TRIGLYCERIDES | - |
dc.subject | SECONDARY PREVENTION | - |
dc.subject | FENOFIBRATE THERAPY | - |
dc.subject | HEART-DISEASE | - |
dc.subject | FATTY-ACIDS | - |
dc.title | Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Nam Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Sin Gon | - |
dc.identifier.doi | 10.4093/dmj.2020.0001 | - |
dc.identifier.scopusid | 2-s2.0-85084170516 | - |
dc.identifier.wosid | 000530045200002 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM JOURNAL, v.44, no.2, pp.213 - 221 | - |
dc.relation.isPartOf | DIABETES & METABOLISM JOURNAL | - |
dc.citation.title | DIABETES & METABOLISM JOURNAL | - |
dc.citation.volume | 44 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 213 | - |
dc.citation.endPage | 221 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002580130 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject.keywordPlus | TYPE-2 DIABETES-MELLITUS | - |
dc.subject.keywordPlus | NON-HDL CHOLESTEROL | - |
dc.subject.keywordPlus | LDL-CHOLESTEROL | - |
dc.subject.keywordPlus | ATHEROGENIC DYSLIPIDEMIA | - |
dc.subject.keywordPlus | REDUCING TRIGLYCERIDES | - |
dc.subject.keywordPlus | SECONDARY PREVENTION | - |
dc.subject.keywordPlus | FENOFIBRATE THERAPY | - |
dc.subject.keywordPlus | HEART-DISEASE | - |
dc.subject.keywordPlus | FATTY-ACIDS | - |
dc.subject.keywordAuthor | Cardiovascular diseases | - |
dc.subject.keywordAuthor | Dyslipidemias | - |
dc.subject.keywordAuthor | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keywordAuthor | Metabolic syndrome | - |
dc.subject.keywordAuthor | Peroxisome proliferator-activated receptors | - |
dc.subject.keywordAuthor | PPAR alpha | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.